A Journey: From Bench Scientist to NIH Program Officer

Jim A. Turpin
Chief, Program Officer
Preclinical Microbicides and Prevention Research Branch (PMPRB)
NIH/NIAID/DAIDS/PSP
DHHS/NIH Required Disclaimer

The views expressed are those of the presenter and do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government

Conflicts of Interest
None to report
I Am Going to Take You On a Journey

“The only real voyage of discovery consists in not seeking new landscapes but in having new ideas”

Marcel Proust
HIV Non-vaccine Biomedical Prevention (nBP)

DEFINITION

✓ A safe, effective and acceptable agent delivered as a single, combination or multi-component strategy
  • Topically—applied to a mucosal surface:
    gel, tablet (insert), film, enema/douche, suppository and/or device (i.e. ring, diaphragm, IUD)
  • Systemically:
    oral, injection, transdermal or implant.

✓ Prevents transmission and acquisition of HIV and possibly other sexually transmitted infections at the female and male genital and gastrointestinal mucosa

✓ For all individuals at risk for HIV infection:
  • HIV negative
  • In a serodiscordant relationship
Some Basic Facts About HIV/AIDS
Risk for HIV Infection

- **Vaginal HIV Transmission**
  Est. Risk per act: 1:100 to 1:1000

- **Rectal HIV Transmission**
  Est. Risk per act: 1:10 to 1:100

*Anal intercourse is not just a “gay man” issue:*

*Depending upon age, race, geographic location, education, poverty status, and gender power relationships estimates are that from 5% to 60% of heterosexual couples may practice receptive anal intercourse (RAI).*

- **Other Forms of Transmission**
  - Intravenous Drug Use (IDU) – 1:1 to 1:10 – depends upon viral load
  - Mother to Child Transmission – With antivirals approaches 0 (without antivirals 1:2 to 1:7)
Global HIV Statistics

Although great progress has been made toward controlling the AIDS Pandemic

2016, HIV infection is the:
Leading cause of death of reproductive age women (15-49 years of age)
Second leading cause of death in women (15-24 years of age) in Africa

*Increases in AIDS-related mortality have occurred over the past decade in the Middle East and North Africa (48% increase) and eastern Europe and central Asia (38% increase).*

![Global summary of the AIDS epidemic 2016](image)

<table>
<thead>
<tr>
<th>Number of people living with HIV</th>
<th>Total</th>
<th>36.7 million [30.8 million–42.9 million]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adults</td>
<td>34.5 million [28.8 million–40.2 million]</td>
</tr>
<tr>
<td></td>
<td>Women (15+ years)</td>
<td>17.8 million [15.4 million–20.3 million]</td>
</tr>
<tr>
<td></td>
<td>Children (&lt;15 years)</td>
<td>2.1 million [1.7 million–2.6 million]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>People newly infected with HIV in 2016</th>
<th>Total</th>
<th>1.8 million [1.6 million–2.1 million]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adults</td>
<td>1.7 million [1.4 million–1.9 million]</td>
</tr>
<tr>
<td></td>
<td>Children (&lt;15 years)</td>
<td>160 000 [100 000–220 000]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AIDS-related deaths in 2016</th>
<th>Total</th>
<th>1.0 million [830 000–1.2 million]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adults</td>
<td>890 000 [740 000–1.1 million]</td>
</tr>
<tr>
<td></td>
<td>Children (&lt;15 years)</td>
<td>120 000 [79 000–160 000]</td>
</tr>
</tbody>
</table>

Translates to

Globally
~5000 new infections a day
~4500 in individuals 15 years or older
43% women
37% ages 14-25
There were an estimated 37,600 new HIV infections in 2016.

Today 1 in 7 (14%) HIV infected individuals do not know they are infected.

An estimated 44% (~2300) of adolescents and young adults age 13 to 29 did not know they were infected with HIV.

African Americans and Hispanics/Latinos are disproportionately affected by HIV. In 2016:

- **African Americans** represented 12% of the population, but accounted for 44% (17,528) of new HIV diagnoses.
- **Hispanics/Latinos** represented 18% of the population, but accounted for 25% (9,766) of new HIV diagnoses.

**US Geographically.** The population rates (per 100,000 people) of people who received an HIV diagnosis were highest in the South (16.8), followed by the Northeast (11.2), the West (10.2), and the Midwest (7.5).
What we know (or think we know) about HIV infection in the female and male genital and gastrointestinal tracts.
What Are the HIV Target Tissues?

TH17 T cells and other cells in the genital and GI tracts are HIV targets

Dendritic Cells, Langerhans Cells and monocyte/macrophages

Sun Tzu
The Art of War
“Know your enemy and know yourself”

Virus Exposure
C. Hendrix, Johns Hopkins
Vaginal and Rectal HIV Transmission

**Proposed Mechanisms for Vaginal Mucosal Transmission of HIV**

1. Infection of Epithelial Cell
2. Transcytosis by M Cell
3. Damaged Epithelial layer

**Proposed Mechanisms for Rectal HIV Transmission**

1. Infection of Epithelial Cell
2. Transcytosis by M Cell
3. Damaged Epithelial layer

- Tear in Vaginal Epithelium
- Diffusion HIV Monocyte
- Langerhan's Cell
- Th17 T cell
- Dendritic Cell
- HIV-lymphocyte

**Enriched in Activated T Cells**

- Galactosyl Ceramides
- R5 + region
- X4 and R5 + region
- CD4+ T cell
- HIV Infected CD4+ T cell (Th17)
- Dendritic cell
Natural Mucosal Barriers to HIV Infection

Adapted from: Cu-Uvin, CROI 2012 and Hector Mendez-Figueroa; Brenna Anderson
How Long Does It Take HIV To Establish Infection?

However, monkey studies suggest dissemination to tissues may occur in a matter of minutes to hours!
A short history of the development of HIV non-vaccine biomedical prevention strategies
An Abbreviated Clinical History of HIV Non-vaccine Biomedical Prevention

**Phase IIB and III Entry Inhibitor Microbicide Trials**
1. Phase III SAVY (C31G) Stopped for Low Incidence
2. Phase II Dextran Sulfate Stopped for Possible Harm
3. Phase II/III HPTN035 PRO2000 and BufferGel – No Efficacy
4. Phase III MDP 301 PRO2000 2% futility, 0.5% No Efficacy

**Phase IIB and III Pre Exposure Prophylaxis (PrEP) Trials**
- Phase III iPrEX: Oral Daily, TDF/FTC 44% Efficacy
- Phase II/III VOICE: Oral Daily, TDF or TDF/FTC No Efficacy
- Phase III Fem PrEP: Oral Daily, TDF/FTC No Efficacy
- Phase III Partners in PrEP: Oral Daily, TDF/FTC No Efficacy

**Pre-Exposure Prophylaxis (PrEP)**
- Phase III TDF2: Oral Daily, TDF/FTV 62% efficacy
- Open Label PROUD: Daily/Deferred, TDF/FTC 86% Efficacy
- Phase III IPREGAY: Daily TDF/FTV 86% Efficacy

**Phase IIB and III Topical Microbicide Antiviral (ARV) Trials**
- Phase II CAPRISA 004 1% Tenofovir gel 37% Efficacy, HSV 51%
- Phase II/III VOICE 1% Tenofovir gel Stopped for Futility
- Phase III FACTS 001 1% Tenofovir gel No Efficacy

**30 day Dapivirine Intravaginal Ring (IVR)**
- Phase III ASPIRE 27% Efficacy
  - Age <21 0% efficacy, >21 65% efficacy
- Phase III The Ring Trial 31% Efficacy
  - Age <21 15% efficacy, >21 37% efficacy
# Clinical Success and Failure – it's all about adherence

## Efficacy: Per Protocol vs. Analytical (Drug in Blood)

<table>
<thead>
<tr>
<th>Study</th>
<th>Per Protocol Efficacy</th>
<th>Drug in Blood Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gay Men and Men who have Sex with Men (MSM)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>iPrEx</td>
<td>44%</td>
<td>73%</td>
</tr>
<tr>
<td>iPrEx OLE</td>
<td>49%</td>
<td>71%</td>
</tr>
<tr>
<td>PROUD</td>
<td>86%</td>
<td>86%</td>
</tr>
<tr>
<td>IPERGAY</td>
<td>82%</td>
<td>86%</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAPRISA 004</td>
<td>37%</td>
<td>50-60%</td>
</tr>
<tr>
<td>FACTS 001</td>
<td>0%</td>
<td>43%</td>
</tr>
<tr>
<td>VOICE</td>
<td>0%</td>
<td>28%</td>
</tr>
<tr>
<td>FemPrEP</td>
<td>0%</td>
<td>6%</td>
</tr>
<tr>
<td><strong>Discordant Couples</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partners in PrEP</td>
<td>67%</td>
<td>82%</td>
</tr>
<tr>
<td>TDF2</td>
<td>62%</td>
<td>84%</td>
</tr>
</tbody>
</table>

Note – a Sub analysis without statistical power to show a “real” effect; whereas’ Per Protocol is powered to identify a statistically significant effect.

- TDF/FTC licensed in U. S. for HIV Prevention as PrEP
- 1% Tenofovir gel
- Before PrEP licensed
- Prior to TDF/FTC PrEP licensure

All Studies Self-Reported Adherence >90%
Lessons Learned from Clinical trials

- If the prevention strategy is used it will probably work.

- Men and Women must desire to use the prevention strategy.
  - Many people do not recognize their risk, this is especially true for adolescents and young adults
  - Recognition of risk does not always translate to prevention strategy use
    
    Make it and they will come is a fallacy

- Self-report of adherence over estimates pharmacological adherence.
  
  must be able to directly measure use, delivery system, placebo and drug in clinical trials

- There are big differences between men and women: TDF/FTC PrEP PK favors less adherence in men vs. women

  When using PrEP to prevent HIV infection:

  - Men: 28% adherence (2-3 doses per week) to prevent HIV infection
  - Women: 85% adherence (6 to 7 pills a week) to prevent HIV infection

Bench Scientist to Program Officer
Education

Small Liberal Arts College
University of Evansville  1976 to 1980
Biology Major, B.S.

Exposed to Immunology, Macrophages and Cancer Immunotherapy

1980  Grad School:
Graduate School of Biomedical Sciences, University of Texas, Houston, TX (UT-GSBS)
Now
MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences
Selected Events

- Tutorials in Immunogenetics, Cancer Immunotherapy and Retrovirology (pre-HIV)
- MD Anderson Hospital
  - Joined Department of Clinical Immunology led by Dr. Evan M. Hersh, MD
    - "Godfather of Cancer Immunotherapy"
- Assigned to new faculty:
  - Dr. Gabriel Lopez Berestein, MD
  - Human Monocytes and Cancer control
- Research Topic:
  - Human monocyte/macrophage maturation and heterogeneity

Relevant Outcomes

1980
- M. S. Dissertation: Oxidative burst heterogeneity during in vitro maturation of human monocytes

1984
- Research Tech.
  - Dr. Josh Fidler, Ph.D.
  - Monocyte activation and tumoricidal activity

1986
- Ph.D. Dissertation: Effect of maturation on the function and tumoricidal activity of human monocytes

1988
- Ph. D. in Biological Sciences with Specialization in Immunology
Science Does Not Happen in Vacuum

**World Events**

- **1981**
  - June 5th, CDC Publishes Morbidity and Mortality Weekly Report (MMWR) 5 young Gay Men rare lung infection \( P. \) carinii
  - July 3rd 41 cases of Kaposi’s sarcoma
  - End of year 207 Cases in gay men 121 deaths

- **1982**
  - September 24th CDC uses term AIDS
  - 10,000 +estimated to be infected

- **1983**
  - First cases in women (Partners of Men infected with AIDS)

- **1984, June**
  - AIDS caused by Virus

- **1987**
  - President Ronald Reagan makes first speech about AIDS and establishes commission

- **December 1, 1988 First World AIDS day**

**Local Happenings**

- **1980**
  - MD Anderson Cancer Clinics:
    - Increase in presentation of Kaposi Sarcoma

- **1982-1983**
  - Multiple CDC briefs at MD Anderson on this new emerging immunodeficiency syndrome
    - Gay men/ men who have sex with men (MSM)
    - Hemophiliacs
    - Women

- **1984**
  - Masters

- **1986**
  - 1988 Ph. D. in Biological Sciences with Specialization in Immunology

- **1987**
  - Seminar: Dr. Monte Meltzer, WRAIR
  - \( HIV \) infects Human Monocytes

**NOTE:** October 26, 1990 AZT licensed by FDA as first treatment for HIV/AIDS
Academia, Contract Research and Government Service

Had a Ph. D. wanted to understand how infections impacted monocyte maturation /differentiation

Research Chemist, Walter Reed Army Institute of Research
Monte Meltzer’s Department

Monocyte/macrophages – Differentiation and disease
HIV Dengue Leishmania Francisella Tularensis (rabbit fever)
Cellular and molecular factors controlling HIV replication in monocytes

Research Scientist, NCI – Frederick, MD
Ft. Detrick, MD

HIV drug and assay development
Introduced to HIV Prevention and Topical Microbicides
Concluded: Anti-HIV drugs could control disease, but not eliminate—all Vaccines were not going to be easy—HIV Prevention was doable

Contract Research Organizations (CRO)
Southern Research Institute, Frederick
Therimmune Research, Inc

PI for NIAID/DAIDS HIV Topical Microbicide Screening Contract
First NIH grant: U19 IPCP development of Cyanovirin-N as a Tropical Microbicide
Regulatory Science --- Meeting the Federal requirement’s to get drugs to clinical testing

National Institute of Allergy and Infectious Diseases, Division of AIDS

Program Officer: May 3, 2003 Started as a Program Officer DAIDS HIV Topical Microbicide Group
2010 Chief of the newly formed Preclinical Microbicides and Prevention Research Branch
Part of A Big Government Organization

National Institutes Health (NIH)

27 Institutes and Centers dedicated to developing new health innovations to increase the health and well-being of Americans and citizens of the World

National Institute of Allergy and Infectious Diseases (NIAID)

Dr. Anthony S. Fauci, MD

National Institutes of Health (NIH)

DHHS

NIAID Mission Conduct and support basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.
Division of AIDS (DAIDS)

DAIDS Mission: End the AIDS Pandemic by understanding the biology of virus infection and by supporting development of new treatment and prevention drugs and strategies for those infected by the HIV virus or at-risk for HIV infection.

5 USG employees
3 Contractors
4 from other branches
Who Defines Missions and Scientific Priorities?

U.S. Congress

Health needs of Americans
World Health Issues

Emerging Health issues

Emerging Diseases

Research priorities

Investigators and advocates

NIH Mission

NIAID Mission and Objectives

DAIDS Scientific Priorities

Grants and Contracts

GRANTS: Fund investigators to carry out basic, nonclinical and clinical research

CONTRACTS: Facilitate research by performing gap-filling activities
The Role of the Program Officer

A view from the NIH bridge: perspectives of a program officer

Marion Zatz

Mol Biol Cell, 2011 Aug 1; doi: 10.1091/mbc.E11-04-0346 PMCID: PMC3145542

Program Officer (PO)

1. Provides policy advice/guidance to grant applicants: grantsmanship, etc.

2. Make funding recommendations to Leadership (POs do not fund, we recommend)

3. Oversee and document the scientific progress of funded research, and research areas

4. Enforces research policies/regulations/laws, e.g. Public Access, Human Subjects, Vertebrate Animal Use, etc.

5. Acts as an advocate for research:
   - The investigator/ grant applicant
   - The research priority, e.g. HIV non-vaccine Biomedical Prevention

6. Develop workshops and consultations to develop Program scientific priorities and communicate them to the scientific community

7. Support priority research by developing funding mechanisms (initiatives and contracts)
What I do at NIH/NIAID/DAIDS/PSP

I am a Program Officer at NIH/NIAID
and
Lead a Branch in the Division of AIDS (DAIDS), Prevention Sciences Program

Job Description:
Support investigator-initiated grants and develop grant and contract programs to support the discovery and development of new HIV Non-vaccine Biomedical Prevention drugs and their delivery systems, and the technologies required to facilitate prevention research.

Succinctly: I support the development of new safe and effective HIV prevention strategies and drugs by overseeing a portfolio of research grants.
Managing Grants and Contracts: It Takes A Village!

Senior Review Official (SRO): Federal Official responsible for contract or grant review and assuring compliance with required by Federal laws and policies on Committees.

Grants Management Official (GMO): Federal Official responsible for assuring all grant awards meet Federal laws and policies governing them.

Grants Management Specialist (GMS): Federal Official responsible for assuring all requirements are documented and Awards the grant after GMO approval.

Contracting Officer (CO): Federal Official responsible for assuring all contract awards meet Federal laws and policies governing contracts.

Contract Specialist (CS): Federal Official responsible for assuring all requirements are documented and awards the contract after CO approval.

Program Officer (PO): Federal Official responsible for assuring Federal and research laws and policies are implemented before and after grant award and tracking the Scientific progress during the award.

Contract Officer Representative (COR): Federal Official responsible for assuring USG Federal contracting laws and policies are implemented before and after contacts award and documenting contract deliverables.

SRO ≠ GMO/GMS ≠ PO
CO/CS ≠ COR

A PO can also be a COR
Program Officer enables scientific priorities through support of grants and contracts

But, how do you translate what we know about HIV and HIV prevention into mechanisms (Grants and Contracts) to fund investigators to create new better HIV prevention strategies?

Or
Predicting the future---how do you identify the science that needs to be funded to advance HIV prevention?
Prevention Drug Development: Specialization Without Specialization

Need some expertise in 3 areas:
- Drug development
- Biobehavioral science
- Regulatory science
  - Preclinical
  - Clinical

Understand the Biology of HIV Susceptibility in the Context of HIV Prevention

**Basic Science**

**Product Development**

- Discovery
- Preclinical Studies
- Safety & Toxicology Studies (Critical Path)

**Clinical Testing**

- I
  - Safety
- II
  - Efficacy
- III
  - Licensure
QUESTION: How do you achieve the integration of preclinical drug development, biobehavioral sciences and regulatory sciences to create new non-vaccine biomedical prevention strategies?

ANSWER: Support investigator-initiated research, communicate scientific priorities and by designing initiatives (grants (RFA)) and contracts (RFP) designed to support research to discover, develop and clinically test new non-vaccine biomedical prevention drugs and strategies

CRITICAL: The scientific scope and objectives of supported science is driven not only by what we know about HIV virology and prevention, but also by what scientific gaps we suspect remain!
The Scientific Scope of Non-Vaccine Biomedical Prevention

Preclinical Drug Development:
• Identify a candidate
• Formulate it—stable, easy to use
• Test it in animals for safety and efficacy (Carcinogenesis, Reproductive, Respiratory, CNS, etc.)
• Understand its in vivo properties (PK, Bioavailability, excretion, metabolism, etc.)

Biobehavioral Science:
• Understand the individual’s needs
• How it will be used
• How it fits into the life of users
• Create a need and desire to use

• Study its safety and in characteristics -- Good Laboratory Practices (GLP)
• Manufacture it-- Good Manufacturing Practices (GMP)
• Do clinical studies— Good Clinical Practices (GCP)
Filling in the Target Area: Three Critical Factors

New drugs and strategies that:

- Do no harm *(preclinical drug development)*
- Products that are more likely to be used *(biobehavioral science)*
- Can be licensed for use *(regulatory science)*
New drugs and strategies that:

- Do no harm *(preclinical drug development)*

- Products that are more likely to be used *(biobehavioral science)*

- Can be licensed for use *(regulatory science)*
Many Factors Can Influence Susceptibility to HIV Infection (Harm)

Mucosal susceptibility to HIV Infection is controlled by multiple factors which in aggregate determine the overall degree of susceptibility to infection.

Exogenous Factors, e.g. IPV Trauma/Injury, STIs, Hormonal Contraception, etc.
Prevention Factors, e.g. products, drug delivery systems.

Decreased Susceptibility

Increased Susceptibility
New drugs and strategies that:

- Do no harm (*preclinical drug development*)
- Products that are more likely to be used (*biobehavioral science*)
- Can be licensed for use (*regulatory science*)
Relationship Between Drug Use (Adherence) and Prevention of HIV Infection (Efficacy)

How do you convince healthy people to protect themselves from a risk that seems remote, when engaging in HIV prevention may result in undesirable drug side-effects and/or harm/social stigma?

Furthermore, the prevention strategy may need to be used from sexual debut to end-of-life, so user wants/needs may change.

Increase adherence and use through:
1. Increasing user choices.
2. Increase convenience---Behaviorally congruency (fits into life and sexual practices).
3. Increase compliance---Design usage into the strategy, e.g. long lasting injectable.
Increase User Choices --- Same Drugs, Different Ways to Delivery

- Gels
  - Fast dissolving
  - Slow dissolving

- Films

- Devices +/- Gels

- Reengineered IUD

- Intravaginal Rings (IVR)
  - Matrix
  - Reservoir
  - Segmented
  - Pod

- Injection

- Quick Dissolve Inserts

- Transdermal patches
  - Diffusion
  - Nano-syringe

- Implants
  - Biodegradable
  - Non-biodegradable

- Foams

- Suppositories
  - Vaginal and Rectal

- Enema/Douche

- Foam
Convenience and Compliance

Timing
- Before Sex (pre-coital)
- After Sex (post-coital)
- Before and After Sex (BAT24)
- Episodically: single dose protects for a period of time, e.g. 1 week
- Sustained/extended release: months to years protection

Behavioral Congruency
- Creating desire—Marketing Science
- Create a product that fits into sexual behavior(s)
- Couple HIV prevention with a prevention behavior that is highly desirable to the user, and maybe actively sought
- Multipurpose Prevention Technologies (MPT) HIV drug +
- STI prevention, e.g. Herpes
- Pregnancy prevention
New drugs and strategies that:

- Do no harm *(preclinical drug development)*
- Products that are more likely to be used *(biobehavioral science)*
- Can be licensed for use *(regulatory science)*
Advancing to Clinical Testing and Licensure

Driven by Laws, Regulations and Guidance’s

LAWS: Code of Federal Regulations (CFR)
- Good Laboratory Practices (GLP: 21 CFR Part 58)
- Good Manufacturing Practices (GMP: 21 CFR part 110-225)
- Good Clinical Practices (GCP: 21 CFR 50,54,56,812,814)
- Data and Computer standards (21 CFR Part 11)
- Good Farming Practices (GFP)—drug made in plants

✓ U.S. Food and Drug Administration (FDA) Guidance’s
  –Issue approx. 100 revised/new guidance's per year!
  - Devices
  - Microbicides
  - Antivirals
  - Combination Drugs
  - Etc.

✓ International Conference on Harmonization (ICH) Guidance's
✓ United States Pharmacopeia (USP)
✓ International Organization for Standardization (ISO)

✓ U. S. and Foreign commerce and drug regulations and laws
Translate Code of Federal Regulations (CFRs) and FDA Guidance’s to Required Preclinical Studies

**General Preclinical Virology**
- Antiviral activity
- Toxicity Cell lines/Primary cells
- Range of Action—Virus Subtypes
- Mechanism of Action
- Mechanism of resistance
- Activity in combination other drugs
- Active in relevant matrices

**Prevention Specific**
- **Lab**
  - Condom Compatibility
  - Effect on Lactobacilli
  - Effect of Matrices
    - Seminal Plasma
    - Cervical fluid
    - Mucin
  - Impact on other STIs
  - Cervical Explants
  - Murine, NHP safety and efficacy

**Specific Mucosal Irritation Testing**
- Vaginal Irritation
- Rectal Irritation
- Penile Irritation

**2 Animal Model Safety, Pharmacokinetics (PK) and Toxicology**
- Maximum tolerated dose (MTD)
- Acute Toxicity
- Chronic Toxicity, 90+ days
- Specific system toxicity, e.g. neuro-, immuo-, cardio-, pulmonary-toxicity etc.
- PK and Metabolites (Absorption, Distribution, Metabolism and Excretion, ADME)
- Genotoxicity
- Carcinogenesis
- Reproductive toxicology
  - Seg. I Reproductive performance
  - Seg. II Teratology
  - Seg. III Perinatal/Post natal
- Dermal/systemic Hypersensitivity
- Dermal/ systemic Photosensitivity
- Extractable and Leachables:
  - Devices
  - Packaging
  - Applicator

**Chemistry Manufacturing and Control (CMC)**
- **Drug**
  - Drug Substance
- **Formulated Drug**
  - Drug Product
- Stability, Sterility, Packaging, Storage

**Applicator**
- Selection
- Stability
- Compatatability
- Labeling
- Acceptability
- Use (Human Factors)
- Filling

**Will it inhibit HIV**
**Reduce the Chance of Harm to Humans**

**Identity: Its what we say it is**
Putting It All Together?

Is there a need?

Marketing

Creating Consumer Demand

Never Ends

Behavioral Factors

Perceptibility
Acceptability
Adherence
Compliance
Voluntary Use

In vitro/vivo Studies
Safety
Pharmacology
Toxicology
Critical Path

Phase 1
Phase 2
Clinical
Testing
SAFETY

Phase 3
Clinical
Testing
Efficacy

Phase IV
Marketing
Studies
MD
prescribed

Generic
Product

OTC
Product

Implementation

Users
Health Care Providers
Policy Makers

Chemistry, Manufacturing and Controls (CMC)
Homogeneity, Purity and Identity (mg to g)

Consumer Manufacturing (tons to kilotons)
Production → QC → Distribution → Last mile

NDA

Federal, State and Local Laws, Regulations and Guidance's

100’s to 1000’s Candidates

1 licensed Drug

Pennies to $1000’s

Millions of Dollars

Pennies/Dollars
FACTOIDS

Time and cost (discovery to approval): **10 to 17 years and $2.6 Billion**

**Probabilities of Success**

*Discovery to Clinical Testing:* ~1%

*Drugs: Phase 1 to approval:* 9-12%

**Clinical testing:**
- 60% drop out in Phase I
- 30% percent drop out in Phase II
- 45% fail in Phase III

NDA-- Successful Phase III candidates only 20-25% are approved (Licensed) as drugs by the FDA

Does not take into account failure of doctors to prescribe or consumers to use

After licensure only 1 of 5 drugs recoup their development cost
**Pipeline Enabling**: Grants designed to **address basic research gaps that enable development** of prevention drugs and strategies.

**Innovation**: Grants designed to **support the high-risk innovative research** required to create new prevention strategies.

**Drug Development**: Grants designed to **advance prevention products through nonclinical safety studies and into First-in-Human clinical testing**.

**Gap-Filling**: Contracts or Grants designed to **overcome barriers to advancement of prevention products or address a specific research topic**, e.g. adolescents in all phases of the development pipeline.
## Summary: Program Officers Do

<table>
<thead>
<tr>
<th>Administrative Duties</th>
<th>Acts as the touch-point and resource for investigators to help them meet grant policies and be successful in their research and enforces research laws, regulations and policies.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Duties</td>
<td>Support and sometimes create programs that address scientific objective(s) of their Institute/Division /Program/Branch.</td>
</tr>
</tbody>
</table>
Wrapping Up

Evolution as a metaphor for what I have become as a Scientist and Program Officer

**Charles Darwin**

“It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is the most adaptable to change.”

**Charles Sanders Peirce (Father of Pragmatism)**

“All the evolution we know of proceeds from the vague to the definite.”

HIV Prevention Strategies

Products that Prevent HIV Infection

Change The World!